Medicare drug price cuts could have limited early impact, but grow with time

The Biden administration struck a triumphant tone on Thursday in rolling out the first drug price cuts negotiated by Medicare, a new authority granted by the Inflation Reduction Act. But the industry and investment community’s response to the long-awaited announcement was mixed, signaling a level of uncertainty as to the law’s true impact on drugmakers going forward.